ClinicalTrials.gg
CompletedNCT00721162Updated Sep 26, 2019Results posted

Study of Ramucirumab in Ovarian Cancer

A Phase 2 interventional study of Ramucirumab in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Eli Lilly and Company. Completed at 13 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Ovarian Neoplasms by Eli Lilly and Company — 6 open to participants now, 9 under way, 1 of them phase 3. Ovarian Neoplasms · Eli Lilly and Company.

Enrollment
21st of 26
60 · median 158
Started
2008
the only one that year
Phase 2
14 of 29
none open now
Registered
15th of 29
by date

Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, this one is the 21st largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2008, is one of 14 in phase 2, and was the 15th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 29 studies in Ovarian Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Ovarian Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.

Read the detailed description

Current chemotherapies used to treat ovarian cancer participants include doxorubicin, topotecan, and paclitaxel, to mention a few. Doxorubicin was studied in ovarian cancer participants that were refractory to paclitaxel and platinum-based chemotherapy agents. Inhibition of angiogenesis is considered a promising approach to the treatment of cancer. Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and is likely an important therapeutic target in persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. VEGF is overexpressed in ovarian tissue and may be the most important single tumor angiogenic factor. Phase 1 studies currently nearing completion with ramucirumab have demonstrated safety and tolerability at clinically relevant doses, with preliminary evidence of clinical efficacy in ovarian cancer participants. Therefore, ImClone Systems plans to conduct a Phase 2 trial to assess the safety and efficacy of ramucirumab in participants with platinum-refractory persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma

Keywords

  • Ovarian Cancer,
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet the following criteria to be enrolled in this study:

  1. The participant has recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic documentation of the original primary tumor is required via a pathology report
  2. The participant has at least one unidimensional-measurable target lesion [≥ 2 centimeter (cm) with conventional techniques, or ≥ 1 cm by spiral computed tomography (CT) or magnetic resonance imaging (MRI)], as defined by (RECIST). Tumors within a previously irradiated field will be designated as "nontarget" lesions unless progression is documented or a is obtained to confirm persistence at least 90 days following completion of radiation therapy
  3. The participant has recovered to Grade ≤ 1 by the National Cancer Institute , Version 3.0 (NCI-CTCAE v3.0) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other targeted therapies for ovarian cancer, with the exception of alopecia or peripheral neuropathy (which must have resolved to Grade ≤ 2). Any other prior therapy directed at the malignant tumor must be discontinued at least three weeks prior to the first dose of study medication, or hormonal therapy discontinued at least one week prior to the first dose of study medication. Continuation of hormone replacement therapy is permitted
  4. The participant has completed at least one platinum-based chemotherapeutic regimen for management of primary disease, and must have at least one of the following: a platinum-free interval of \< 12 months after the final dose of primary platinum-based therapy, progression during platinum-based therapy, or persistent disease after platinum-based therapy
  5. The participant has an Performance Status (ECOG PS) of 0-1 at study entry
  6. The participant has adequate hematological functions [ (ANC) ≥ 1200 cells/microliter (uL), ≥ 9 grams/deciliter (g/dL), and ≥ 100,000 cells/uL]
  7. The participant has adequate hepatic function [ ≤ 1.5 times the (ULN); (AST) and/or alanine transaminase (ALT) ≤ 3.0 times ULN, or ≤ 5.0 times ULN if the transaminase elevation is due to liver ]
  8. The participant has adequate renal function [serum creatinine ≤ 1.5 x ULN or (measured or calculated) ≥ 60 milliliters/minute (mL/min)]
  9. The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicated ≥ 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate \< 1000 milligrams (mg) of protein in 24 hours to allow participation in the study
  10. The participant has adequate coagulation function, as defined by (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin, and if on warfarin must have therapeutic INR and have no active bleeding (defined as within 14 days of first dose of study medication) or pathological condition that carries a high risk of bleeding (example, tumor involving major vessels or known varices)
  11. For participants who have received anthracycline therapy, the (LVEF) must be within normal institutional range by a pretreatment echocardiogram or multigated acquisition (MUGA) scan
  12. If sexually active, the participant is , surgically sterile, or using effective in the opinion of the investigator
  13. The participant is ≥ 18 years of age
  14. The participant has a of ≥ 3 months
  15. The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing

Exclusion criteria

Exclusion Criteria:

  1. The participant has a concurrent active , other than adequately treated nonmelanomatous skin cancer or other noninvasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible provided that she has been disease-free for > 3 years
  2. The participant has received a noncytotoxic regimen (usually called targeted therapy such as bevacizumab) for recurrent or persistent disease. (Participants may have received a noncytotoxic regimen as primary treatment.)
  3. The participant has received radiotherapy for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within 3 weeks (21 days) prior to the first dose of study medication
  4. The participant has received prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last 3 years. [Prior radiation for localized cancer (for example, of the breast, head and neck, or skin) is permitted, provided that it was completed > 3 years prior to the first dose of study medication, and the participant remains free of recurrent or disease.]
  5. The participant has received prior chemotherapy for any abdominal or pelvic tumor, other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer \< 3 years prior to the first dose of study medication. Prior chemotherapy for localized breast cancer is permitted, provided that it was completed >3 years prior to the first dose of study medication, and that the participant remains free of recurrent or metastatic disease
  6. The participant has undergone major abdominal surgery within 4 weeks (28 days) prior to first dose of study medication
  7. The participant has a suspected impending bowel obstruction, based on clinical or radiographic criteria
  8. The participant has received any hormonal therapy directed at the malignant tumor discontinued therapy within 1 week (7 days) prior to first dose of study medication
  9. The participant has received any other prior therapy directed at the malignant tumor, including immunologic agents, within 3 weeks (21 days) prior to first dose of study medication
  10. The participant has received previous treatment with ramucirumab
  11. The participant has participated in clinical trials of experimental agents within 4 weeks (28 days) prior to first dose of study medication
  12. The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
  13. The participant has an ongoing or active infection requiring systemic antibiotics, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, myocardial infarction \< 6 months, Grade ≥ 2 peripheral vascular disease, poorly controlled hypertension despite standard medical management poorly controlled thrombotic or hemorrhagic disorder, psychiatric illness or social situations that would limit compliance with study requirements, or any other serious uncontrolled medical disorders in the opinion of the investigator
  14. The participant has any history of or . Screening for central nervous system (CNS) involvement for testing asymptomatic participants is not required
  15. The participant has known infection or acquired immunodeficiency syndrome-related illness
  16. The participant is pregnant [confirmed by serum beta human chorionic gonadotropin (β-HCG) test] or lactating
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Ramucirumab

    Biological: Ramucirumab

Interventions

  • BiologicalRamucirumab

    Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.

    Also known as: IMC-1121B

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6)

    Data presented are the percentage of participants without progressive disease (PD) or death from any cause at 6 month after first dose. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion.

    Time frame: First Dose to 6 Months

  2. Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) and Partial Response (PR)

    Objective response is confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression/recurrence or the start of new therapeutic anticancer treatment, whichever occurred first, divided by the total number of participants treated, then multiplied by 100.

    Time frame: First dose to date of objective progressive disease /death or new anti-cancer therapy up to 34.6 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment.

    Time frame: First dose to measured progressive disease or death due to any cause up to 34.6 months

  2. Overall Survival at 1 Year (OS-1)

    Data presented are the percentage of participants surviving at least 12 months after first dose based on Kaplan Meier Method.

    Time frame: First dose to 12 months

  3. Overall Survival (OS)

    Overall survival is defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, overall survival was censored on the last date the participant was known to be alive.

    Time frame: First dose to death due to any cause up to 43.9 months

  4. Summary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events

    Data presented are the number of participants who experienced treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or 4 TEAE, or adverse events (AE) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: First dose to 30 months

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab
Started60
Received any amount of study drug60
Completed60
Not completed0

Outcome measures

PrimaryPercentage of Participants With Progression-Free Survival at 6 Months (PFS-6)

Data presented are the percentage of participants without progressive disease (PD) or death from any cause at 6 month after first dose. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion.

Time frame:
First Dose to 6 Months
Reported as:
Number · percentage of participants
Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6)
percentage of participantsRamucirumab
Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6)25.0 (14.7 to 37.9)
PrimaryObjective Response Rate (ORR): Percentage of Participants With Complete Response (CR) and Partial Response (PR)

Objective response is confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression/recurrence or the start of new therapeutic anticancer treatment, whichever occurred first, divided by the total number of participants treated, then multiplied by 100.

Time frame:
First dose to date of objective progressive disease /death or new anti-cancer therapy up to 34.6 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) and Partial Response (PR)
percentage of participantsRamucirumab
Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) and Partial Response (PR)5.0 (1.0 to 13.9)
SecondaryProgression-Free Survival (PFS)

Defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment.

Time frame:
First dose to measured progressive disease or death due to any cause up to 34.6 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsRamucirumab
Progression-Free Survival (PFS)3.5 (2.3 to 5.3)
SecondaryOverall Survival at 1 Year (OS-1)

Data presented are the percentage of participants surviving at least 12 months after first dose based on Kaplan Meier Method.

Time frame:
First dose to 12 months
Reported as:
Number · percentage of participants
Overall Survival at 1 Year (OS-1)
percentage of participantsRamucirumab
Overall Survival at 1 Year (OS-1)48.0 (34.9 to 59.9)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, overall survival was censored on the last date the participant was known to be alive.

Time frame:
First dose to death due to any cause up to 43.9 months
Reported as:
Median · months
Overall Survival (OS)
monthsRamucirumab
Overall Survival (OS)11.1 (8.3 to 17.0)
SecondarySummary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events

Data presented are the number of participants who experienced treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or 4 TEAE, or adverse events (AE) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
First dose to 30 months
Reported as:
Number · participants
Summary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events
participantsRamucirumab
Related TEAE56
Related SAE10
Related Grade 3 or 4 TEAE21
Related AE leading to discontinuation4

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab—22/60 (36.7%)58/60 (96.7%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventRamucirumab
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/60
Small intestinal obstructionGastrointestinal disorders3/60
Expired drug administeredInjury, poisoning and procedural complications3/60
Intestinal perforationGastrointestinal disorders2/60
Alanine aminotransferase increasedInvestigations2/60
ThrombocytopeniaBlood and lymphatic system disorders1/60
Mitral valve incompetenceCardiac disorders1/60
AscitesGastrointestinal disorders1/60
GastritisGastrointestinal disorders1/60
NauseaGastrointestinal disorders1/60
Most frequent other events
Showing 10 of 50
Most frequent other events
EventRamucirumab
HeadacheNervous system disorders43/60
FatigueGeneral disorders41/60
NauseaGastrointestinal disorders26/60
DiarrhoeaGastrointestinal disorders21/60
VomitingGastrointestinal disorders20/60
Oedema peripheralGeneral disorders16/60
HypertensionVascular disorders16/60
ConstipationGastrointestinal disorders13/60
Urinary tract infectionInfections and infestations13/60
CoughRespiratory, thoracic and mediastinal disorders13/60

Baseline characteristics

All participants who received any amount of study drug.

Age, Categorical
Age, Categorical(Participants)Ramucirumab
<=18 years0
Between 18 and 65 years36
>=65 years24
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab
Female60
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab
Hispanic or Latino1
Not Hispanic or Latino59
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ramucirumab
Black or African American5
White52
Other3
Region of Enrollment
Region of Enrollment(participants)Ramucirumab
United States56
United Kingdom4
08

Study locations

13 sites
  • ImClone Investigational Site
    Hollywood, Florida 33021, United States
  • ImClone Investigational Site
    Orlando, Florida 32806, United States
  • ImClone Investigational Site
    Chicago, Illinois 60637, United States
  • ImClone Investigational Site
    Marrero, Louisiana 70072, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Baltimore, Maryland 21237, United States
  • ImClone Investigational Site
    Boston, Massachusetts 02114-2621, United States
  • ImClone Investigational Site
    Rochester, Minnesota 55905, United States
  • ImClone Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • ImClone Investigational Site
    Houston, Texas 77030-4009, United States
  • ImClone Investigational Site
    Seattle, Washington 98104, United States
  • ImClone Investigational Site
    London, SW3 6JJ, United Kingdom
  • ImClone Investigational Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep;134(3):478-85. doi: 10.1016/j.ygyno.2014.06.029. Epub 2014 Jul 10. PubMed 25016924 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of May 2012 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 1 month after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2008
First posted
Jul 23, 2008
Start
Aug 2008
Primary completionActual
May 2012
CompletionActual
Aug 2015
Results delay requested
Aug 25, 2010
Results first posted
Jun 18, 2014
Last update
Sep 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00721162
Responsible party
Sponsor
First posted
Jul 23, 2008
Start date
Aug 2008
Primary completion
May 2012
Completion
Aug 2015
Results posted
Jun 18, 2014
Last update
Sep 26, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion